Inhibition of pain responses by activation of CB2 cannabinoid receptors

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 191-200

  Malan Jr , T Philip ^a   Ibrahim, Mohab M ^a   Vanderah, Todd W ^a   Makriyannis, Alexandros ^b   Porreca, Frank ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Allodynia; Cannabinoid; CB2; Hyperalgesia; Inflammation; Neuropathic; Pain

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; RIMONABANT;

AGONIST; ALLODYNIA; ANTINOCICEPTION; CENTRAL NERVOUS SYSTEM; CHEMICAL ANALYSIS; CONFERENCE PAPER; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG SPECIFICITY; DRUG SYNTHESIS; EDEMA; HYPERALGESIA; INFLAMMATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; STIMULUS RESPONSE;

ANIMALS; HUMANS; INFLAMMATION; PAIN; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0037207084     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00155-X     Document Type: Conference Paper

References (59)

1. Ali Z., Ringkamp M., Hartke T.V., Chien H.F., Flavahan N.A., Campbell J.N., Meyer R.A. Uninjured C-fiber nociceptors develop spontaneous activity and alpha-adrenergic sensitivity following L6 spinal nerve ligation in monkey. J. Neurophysiol. 81:1999;455-466.
2. Bayewitch M., Avidor-Reiss R., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition of G protein coupling. FEBS Lett. 375:1995;143-147.
3. Bennett D.L., French J., Priestley J.V., McMahon S.B. NGF but not NT-3 or BDNF prevents the A fiber sprouting into lamina II of the spinal cord that occurs following axotomy. Mol. Cell Neurosci. 8:1996;211-220.
4. Bharali L.A., Lisney S.J. The relationship between unmyelinated afferent type and neurogenic plasma extravasation in normal and reinnervated rat skin. Neuroscience. 47:1992;703-712.
5. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Le Fur G., Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214:1993;173-180.
6. Bridges D., Ahmad K., Rice A.S. The synthetic cannabinoid WIN55, 212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol. 133:2001;586-594.
7. 2 receptor. Eur. J. Pharmacol. 396:2000;141-149.
8. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
9. Calignano A., La Rana G., Giuffrida A., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 419:2001;191-198.
10. Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. 96:2002;253-261.
11. Daemen M.A., Kurvers H.A., Kitslaar P.J., Slaaf D.W., Bullens P.H., Van den Wildenberg F.A. Neurogenic inflammation in an animal model of neuropathic pain. Neurol. Res. 20:1998;41-45.
12. Daemen M., Kurvers H., Bullens P., Barendse G., Van Kleef M., Van den Wildenberg F. Neurogenic inflammation and reflex sympathetic dystrophy (in vivo and in vitro assessment in an experimental model). Acta Orthop. Belg. 64:1998;441-447.
13. Delleminjin P. Are opioids effective in relieving neuropathic pain. Pain. 80:1999;453-462.
14. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
15. Farquhar-Smith W.P., Rice A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 94:2001;507-513.
16. 2 receptors. Mol. Pharmacol. 48:1995;443-450.
17. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
18. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., LeFur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
19. Gilbert P.E. A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog. J. Clin. Pharmacol. 21:1981;311S-319S.
20. 2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 339:1997;53-61.
21. 2 receptor absence in the rat central nervous system. Eur. J. Pharmacol. 377:1999;117-125.
22. 2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA. 96:1999;14228-14233.
23. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
24. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221:1997;157-160.
25. Hohmann A.G., Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90:1999;923-931.
26. Hohmann A.G., Briley E.M., Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 822:1999;17-25.
27. Hong, Y., Cao, C.Q., Payza, K., St-Onge, S., Salois, D., Coupal, M., Fleurent, M., Godbout, C., Dray, A., Perkins, M., 2001. CB2 receptor-mediated suppression of hypersensitivity in the rats with persistent inflammation. Society for Neuroscience Annual Meeting Abstracts 716.4.
28. 2 receptor agonist, relieves neuropathic pain. Society for Neuroscience Annual Meeting Abstracts 716.16.
29. Lambert D.M., Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic. Curr. Med. Chem. 6:1999;757-773.
30. Lambert D.M., DiPaolo F.G., Sonveaux P., Kanyonyo M., Govaerts S.J., Hermans E., Bueb J., Delzenne N.M., Tschirhart E.J. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta. 1440:1999;266-274.
31. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
32. Liu C.N., Wall P.D., Ben-Dor E., Michaelis M., Amir R., Devor M. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. Pain. 85:2000;503-521.
33. Liu X., Eschenfelder S., Blenk K.H., Janig W., Habler H. Spontaneous activity of axotomized afferent neurons after L5 spinal nerve injury in rats. Pain. 84:2000;309-318.
34. 2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
35. 2 cannabinoid receptor agonist AM1241. American Society of Anesthesiologists Annual Meeting Abstracts A-894.
36. 2 cannabinoid receptor activation relieves acute, tonic and neuropathic pain. American Society of Anesthesiologists Annual Meeting Abstracts A-978.
37. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
38. Martin W.J., Patrick S.L., Coffin P.O., Tsou K., Walker J.M. An examination of the central sites of action on cannabinoid -induced antinociception in the rat. Life Sci. 56:1995;2103-2109.
39. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:1996;227-236.
40. McMahon S.B., Bennett D.L., Priestly J.V., Shelton D.L. The biological effects of endogenous nerve factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat. Med. 1:1995;774-780.
41. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359:1998;1-18.
42. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
43. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 65:1999;637-644.
44. 2 receptors. Pharmacol. Ther. 74:(2):1997;129-180.
45. Price, T.J., Dussor, G.D., Hargreaves, K.M., Flores, C.M., 2001. Expression and distribution of cannabinoid receptor subtypes in trigeminal ganglion: Colocalization with nociceptive markers. Society for Neuroscience Annual Meeting Abstracts 716.13.
46. Richardson J.D. Cannabinoids modulate pain by multiple mechanisms of action. J. Pain. 1:2000;2-14.
47. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur. J. Pharmacol. 345:1998;145-153.
48. 1 receptors. Pain. 75:1998;111-119.
49. 2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
50. 9-THC). J. Pharmacol. Exper. Ther. 186:1973;646-654.
51. Smith P.B., Martin B.R. Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia 1992. Brain Res. 578:(1-2):1992;8-12.
52. 1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
53. Verge V.M., Richardson P.M., Wiesenfeld-Hallin Z., Hokfelt T. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. Neuroscience. 15:1995;2081-2096.
54. Wartmann M., Campbell D., Subramanian A., Burstein S.H., Davis R.J. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359:1995;133-136.
55. Woolf C.J., Safieh-Garabedian B., Ma Q.P., Crilly P. Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 62:1994;327-331.
56. Wu G., Ringkamp M., Hartke T.V., Murinson B.B., Campbell J.N., Griffin J.W., Meyer R.A. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J. Neurosci. 21:2001;RC140.
57. Yaksh T.L. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;334S-340S.
58. Yonehara N., Yoshimura M. Influence of painful chronic neuropathy on neurogenic inflammation. Pain. 92:2001;259-265.
59. 1 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5780-5785.